RUNX1 and myocardial infarction: By utilizing various approaches to inhibit RUNX1 in mice following MI, including an adenoviral vector expressing Runx1-shRNA, a cardiotropic adeno-associated virus serotype 9 (AAV9) expressing a shRNA targeting Runx1, and a small molecule inhibitor (Ro5-3335), this study showed that both gene therapeutic and pharmacological approaches to antagonize RUNX1 preserve cardiac function following MI (Martin et al. 2023).